BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Stock Position Decreased by Connor Clark & Lunn Investment Management Ltd.

Connor Clark & Lunn Investment Management Ltd. lowered its holdings in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) by 12.8% during the third quarter, HoldingsChannel.com reports. The fund owned 682,324 shares of the biotechnology company’s stock after selling 100,340 shares during the period. Connor Clark & Lunn Investment Management Ltd.’s holdings in BioCryst Pharmaceuticals were worth $5,186,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds and other institutional investors also recently bought and sold shares of the stock. Counterweight Ventures LLC lifted its holdings in shares of BioCryst Pharmaceuticals by 591.7% in the 3rd quarter. Counterweight Ventures LLC now owns 93,384 shares of the biotechnology company’s stock worth $710,000 after purchasing an additional 79,884 shares during the last quarter. Aigen Investment Management LP increased its position in BioCryst Pharmaceuticals by 75.0% in the third quarter. Aigen Investment Management LP now owns 28,661 shares of the biotechnology company’s stock worth $218,000 after buying an additional 12,280 shares during the period. Principal Financial Group Inc. lifted its stake in BioCryst Pharmaceuticals by 1,058.1% in the third quarter. Principal Financial Group Inc. now owns 411,414 shares of the biotechnology company’s stock valued at $3,127,000 after buying an additional 375,890 shares during the last quarter. Rice Hall James & Associates LLC boosted its holdings in shares of BioCryst Pharmaceuticals by 4.0% during the third quarter. Rice Hall James & Associates LLC now owns 2,163,743 shares of the biotechnology company’s stock valued at $16,444,000 after acquiring an additional 84,102 shares during the period. Finally, China Universal Asset Management Co. Ltd. grew its position in shares of BioCryst Pharmaceuticals by 64.1% during the third quarter. China Universal Asset Management Co. Ltd. now owns 39,791 shares of the biotechnology company’s stock worth $302,000 after acquiring an additional 15,544 shares during the last quarter. 85.88% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several analysts recently weighed in on BCRX shares. Royal Bank of Canada reiterated an “outperform” rating and issued a $10.00 price objective on shares of BioCryst Pharmaceuticals in a research report on Tuesday, November 5th. StockNews.com upgraded BioCryst Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Tuesday, August 6th. JMP Securities raised their target price on BioCryst Pharmaceuticals from $15.00 to $16.00 and gave the company a “market outperform” rating in a research report on Tuesday, August 6th. Needham & Company LLC reaffirmed a “buy” rating and set a $14.00 target price on shares of BioCryst Pharmaceuticals in a research note on Tuesday, November 5th. Finally, Barclays increased their price target on BioCryst Pharmaceuticals from $7.00 to $8.00 and gave the stock an “equal weight” rating in a research note on Tuesday, November 5th. One equities research analyst has rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $15.60.

BioCryst Pharmaceuticals Price Performance

BCRX opened at $7.60 on Friday. The business has a 50 day moving average price of $7.66 and a two-hundred day moving average price of $7.22. The company has a market capitalization of $1.57 billion, a price-to-earnings ratio of -12.46 and a beta of 1.89. BioCryst Pharmaceuticals, Inc. has a 1-year low of $4.03 and a 1-year high of $8.88.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last announced its quarterly earnings data on Monday, November 4th. The biotechnology company reported ($0.07) earnings per share for the quarter, meeting the consensus estimate of ($0.07). The firm had revenue of $117.10 million during the quarter, compared to analyst estimates of $113.99 million. The company’s quarterly revenue was up 35.1% compared to the same quarter last year. During the same quarter last year, the company earned ($0.19) EPS. Equities analysts expect that BioCryst Pharmaceuticals, Inc. will post -0.38 EPS for the current fiscal year.

About BioCryst Pharmaceuticals

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.